Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance


Background The identification and characterization of molecular biomarkers has helped to revolutionize non-small-cell lung cancer (NSCLC) management, as it transitions from target-focused to patient-based treatment, centered on the evolving genomic profile of the individual. Determination of epidermal growth factor receptor (EGFR) mutation status represents… (More)
DOI: 10.18632/oncotarget.24624


5 Figures and Tables